Science AI Journal
Medicine · Research topic

Open research questions in Treatment of Major Depression

354 unresolved questions extracted from the limitations and future-work sections of 2,010 Treatment of Major Depression papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • One challenge is the limited access to care for patients with treatment-resistant depression, with delayed diagnosis and limited specialist services. Another challenge is the potential for adverse effects from pharmacological augmentation, including metabolic, sedative, and cardiovascular risks. The paper also highlights the challenge of implementing evidence-based treatments in real-world clinical practice, with considerations for service feasibility and delivery.

    Pharmacological augmentation for people with treatment-resistant depression · 2026 · DOI

  • Head-to-head and pragmatic data are needed to establish pramipexole's position in augmentation treatment steps, - Further evidence is needed to establish optimal doses, or modified-release preparations for pramipexole, - Guidelines should incorporate the durability of benefit, tolerability, treatment burden and service feasibility

    Pharmacological augmentation for people with treatment-resistant depression · 2026 · DOI

  • Further clinical trials of 5-HT 4 R agonists are needed, - Investigation of procognitive and mood effects of 5-HT 4 R agonists is needed, - Research on the potential of selective serotonin 4 receptor (5-HT 4 R) agonists in the treatment of depression and cognition

    Early effects of a novel 5-HT 4 R agonist (PF-04995274) and the SSRI citalopram on emotional cognition in unmedicated depression: RESTAND study · 2026 · DOI

  • There is a lack of experimental research in clinical populations on the effects of 5-HT 4 R agonists. There is a need to investigate the early effects of 5-HT 4 R agonists on emotional cognition in unmedicated depression.

    Early effects of a novel 5-HT 4 R agonist (PF-04995274) and the SSRI citalopram on emotional cognition in unmedicated depression: RESTAND study · 2026 · DOI

  • The study faced challenges in terms of participant attrition and loss to follow-up. The study had to balance the need for a flexible dosing regimen with the potential for increased side effects. The study had to consider the potential impact of prior ketamine treatment on subsequent response.

    Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study · 2026 · DOI

  • The study had a relatively small sample size, - There was potential 'early adopter' selection bias of initial trial recruitment of more unwell participants, - Loss to follow-up reasons are mostly unknown, - The study was an open label extension

    Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study · 2026 · DOI

  • Current antidepressants do not address cognitive impairment. There is a need for therapeutics that target the HPA axis and/or cortisol regulation/action.

    A Phase 2 randomised, double-blind, placebo-controlled trial of emestedastat in patients with major depressive disorder and cognitive impairment · 2026 · DOI

  • The factors that contribute to antidepressant discontinuation and change patterns are not well understood. There is a need to identify clinical and genetic factors associated with treatment outcomes.

    Understanding antidepressant change patterns in the UK Biobank · 2026 · DOI

  • There are no well-validated, quantitative predictors of treatment response that can guide the selection of pharmacological interventions based on the likely clinical outcome. The current approach to selecting antidepressants is often based on a trial-and-error approach, which prolongs the time to remission and increases healthcare costs. There is an urgent need for reliable methods to predict antidepressant response and inform evidence-based, individualized medication selection.

    Toward precision psychiatry: integrating pharmacogenomics and multimodal clinical data for personalized antidepressant response prediction · 2026 · DOI

  • Investigate the long-term effects of 5-HT 4 R agonism on cognitive function in individuals with a history of depression, - Examine the effects of 5-HT 4 R agonism on cognitive function in other populations, such as those with anxiety disorders

    Pro-cognitive effects of 5-HT4 receptor agonism in individuals with remitted depression · 2026 · DOI

  • Treatment options targeting cognitive dysfunction in depression remain limited. The effects of 5-HT4R agonism on cognition in individuals with remitted depression are not well understood.

    Pro-cognitive effects of 5-HT4 receptor agonism in individuals with remitted depression · 2026 · DOI

  • One challenge is the potential for confounding variables to affect the results, which the study addressed through propensity score matching. Another challenge is the limited generalizability of the results to patients outside of the study population. A third challenge is the potential for bias in the electronic health records used in the study.

    Psychiatric safety of methylphenidate in adults with major depressive disorder: a 1-year retrospective cohort study of 6,422 patients · 2026 · DOI

  • Longer-term studies are needed to fully assess the safety and efficacy of methylphenidate, - Studies examining the effects of methylphenidate on specific subgroups of patients with MDD are needed, - Research on the optimal dosage and duration of methylphenidate treatment is required

    Psychiatric safety of methylphenidate in adults with major depressive disorder: a 1-year retrospective cohort study of 6,422 patients · 2026 · DOI

  • The paper identifies the challenge of treating adolescents and young adults with emotional and relationship difficulties - It notes the complexity of the adolescent mental health crisis - It highlights the need for new approaches to treat this population

    A longitudinal analysis of the clinical practice of ketamine assisted psychotherapy with adolescents and young adults · 2026 · DOI

  • Further studies are needed to confirm the effectiveness of KAP in larger samples - Studies should investigate the long-term effects of KAP - Research should examine the feasibility and effectiveness of KAP in different settings and populations - Studies should explore the optimal dosing strategies and treatment protocols for KAP

    A longitudinal analysis of the clinical practice of ketamine assisted psychotherapy with adolescents and young adults · 2026 · DOI

  • Limited understanding of the factors associated with antidepressant response. Need for personalized treatment strategies. Gap in knowledge regarding the genetic predictors of antidepressant response.

    Sociodemographic, clinical, and genetic factors associated with self-reported antidepressant response outcomes in the UK Biobank · 2025 · DOI

  • investigate the long-term effects of iTBS+D-cycloserine on suicidal ideation, - examine the efficacy of iTBS+D-cycloserine in other psychiatric conditions

    Intermittent theta-burst stimulation with adjunctive D-cycloserine rapidly resolves suicidal ideation and decreases implicit association with death/suicide · 2025 · DOI

  • The impact of iTBS+D-cycloserine on suicide risk is not known. There is a need for effective treatments to reduce suicidal ideation and implicit suicide risk in depression.

    Intermittent theta-burst stimulation with adjunctive D-cycloserine rapidly resolves suicidal ideation and decreases implicit association with death/suicide · 2025 · DOI

  • Cognitive impairment is a significant manifestation of MDD, but its relationship with depressive symptoms remains unclear. The study requires longitudinal analysis to examine the temporal relationships between cognitive function and emotional symptoms in patients with MDD. The paper needs to clarify directional relationships among the symptoms and these symptoms' impacts on the restoration of social functioning.

    A longitudinal analysis of the relationship between emotional symptoms and cognitive function in patients with major depressive disorder · 2025 · DOI

  • The relationship between emotional symptoms and cognitive impairments in major depressive disorder remains unclear. Current diagnostic criteria do not fully capture the complexity of cognitive disturbances in MDD. There is a need for longitudinal analysis to examine the temporal relationships between cognitive function and emotional symptoms in patients with MDD.

    A longitudinal analysis of the relationship between emotional symptoms and cognitive function in patients with major depressive disorder · 2025 · DOI

  • There is a lack of understanding of which aspects of anhedonia are linked to the heterogeneity of treatment responses in major depressive disorder (MDD). Prior studies have reported that anhedonia predicts worse treatment outcome in people with MDD, but none of these studies used a specific measure of anhedonia or monotherapy with a serotonin-reuptake inhibitor antidepressant.

    Which aspects of anhedonia predict response to pharmacotherapy in major depressive disorder? · 2025 · DOI

  • Skeptical clinicians often distrust 'new' diagnostic entities. Disappointing findings from randomized placebo-controlled treatment studies may have disincentivized biotechnology companies. The lack of an established treatment for the condition represents a significant block to its recognition by health professionals.

    ‘Here today, gone tomorrow’ – what happened to recurrent brief depression? · 2025 · DOI

  • small samples, - most investigations being in the first rather than the second decade, - disappointing findings from randomized placebo-controlled treatment studies, - lack of an established treatment for the condition

    ‘Here today, gone tomorrow’ – what happened to recurrent brief depression? · 2025 · DOI

  • The lack of consensus on the definition of TRD. The need for a clear treatment algorithm for TRD. The limited understanding of the neurobiological mechanisms underlying TRD.

    Treatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects · 2025 · DOI

  • The study identifies the challenge of exploring the influencing factors of olanzapine and quantifying the degree of influence. The study also identifies the challenge of formulating an optimal olanzapine dosage in patients with major depressive disorder. The lack of blood concentration information is a challenge in providing a reference for the initial dosage of olanzapine.

    Drug-drug interaction of paroxetine on olanzapine and initial dosage optimization in patients with major depressive disorder based on population pharmacokinetics · 2025 · DOI

Most-cited papers in Treatment of Major Depression

Most recent work

Find a gap in your own Treatment of Major Depression sub-topic

This page shows what the Treatment of Major Depression literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 4.5M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,404 open questions
Substance Abuse Treatment and Outcomes
2,046 open questions
Dementia and Cognitive Impairment Research
1,148 open questions
Smoking Behavior and Cessation
1,056 open questions
Innovations in Medical Education
1,015 open questions
Physical Activity and Health
1,010 open questions
Attention Deficit Hyperactivity Disorder
970 open questions
Schizophrenia research and treatment
962 open questions
354 open questions have been extracted from the limitations and future-work passages of 2,010 Treatment of Major Depression papers in our 4.5M-paper local library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.